During recent months, trials have been undertaken with three relatively new substances in the treatment of non-gonococcal urethritis in males.
Two of these, novobiocin and spiramycin, are antibiotics. Novobiocin (also known as Streptonivicin, Albamycin, Cathomycin, Cathocin) has been prepared from the Streptomyces niveus and from Streptomyces spheroides and was developed in the United States. Also, it has been shown that Cardelmycin is the same substance. Spiramycin (Rovamycin), on the other hand, was developed in France and is prepared from the Streptomyces ambofaciens.
The third substance, Aminitrozole (2-acetylamino-5-nitrothiazole), has been used successfully for some years to prevent enterohepatitis (blackhead No attempt has been made to differentiate relapse from re-infection. Of 87 patients treated with spiramycin, 77 were followed and there were sixteen failures (20 8 per cent.) within 2 to 3 months of observation. Of forty patients treated with Novobiocin, 36 were followed and there were twenty failures (55-6 per cent.). Of 49 treated with aminitrozole, 45 were followed and there were 22 failures (48 9 per cent.).
In Table IV (opposite), these results are compared with those in other previously untreated cases, treated by different means under similar conditions and criteria of study. 
